Manríquez-Reyes M, Martínez-Mier G, Ávila-Pardo SF, Méndez-López MT, Hernández-Jiménez JD, Hernández-Navarrete LS

Language: Spanish
References: 11
Page: 10-14
PDF size: 70.56 Kb.

ABSTRACT

Introduction: Cytomegalovirus is a herpes virus which causes infections in 30-80% of patients with a transplant organ. There are categories of risk in patients undergoing transplantation in relation to cytomegalovirus. Two strategies are used to prevent cytomegalovirus: universal prophylaxis and preemptive therapy. The aim of this study was to determine through a survey, the opinion of cytomegalovirus prophylaxis in the transplant community in our country. Methods: Survey applied during the XVI Congress of the National Society of Transplantation (26-29 September 2012) to health professionals in transplantation and members of Mexican Society of Transplantation. Results: We collected 83 surveys. The average age of respondents was 41 years, 54% were men. 42% percent of respondents have a surgical specialty related to transplantation and 31% a clinical specialty. The largest number came from the Distrito Federal (21.7%) with presence of 19 Mexican states. 66.3% had experience with the disease and 59% have a manual of procedures for it. The transplant more likely to suffer from cytomegalovirus was deceased donor transplants (63.9%) and the high-risk group (D+/R-) is the most frequently in their centers. The universal prophylaxis is more common than preemptive therapy and the preferred scheme is 100 days of valganciclovir (37.3%). Conclusions: Exercises like this survey reveal important information nationally about the infection/cytomegalovirus disease. Prophylaxis schemes should be reviewed according to current international consensus (200 days).

REFERENCES

1. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin Transplant 2007; 21: 149-58.

2. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1-155.

3. Kotton CN, Kumar D, Caliendo AM et al. Transplantation Society International CMV Consensus Group. International Consensus Guidelines on the Management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95.

4. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-20.

5. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-37.

6. Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-31.

7. Arellano-Torres EM, Guerrero-González E, Sánchez-Ramírez H et al. Trasplante renal. Experiencia en el Hospital Universitario “José E. González”, UANL, en Monterrey, México. Rev Invest Clin 2011; 63 (Supl. 1): 25-9.

8. González-Audiffred N, Alfaro-Abúndiz FG, Aranda-Verástegui F et al. Experiencia en trasplante renal, de 1999-2011, en el Hospital Central “Dr. Ignacio Morones Prieto” de San Luis Potosí. Rev Invest Clin 2011; 63 (Supl. 1): 38-43.

9. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF et al. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center. Transplantation 2006; 82: 1533-6.

10. Hernández-Jiménez JD, Hernández-Navarrete LS, Rodríguez-Fernández et al. Experiencia a largo plazo del programa de trasplante renal del Hospital Regional de Veracruz. Rev Mex Tras 2012; 1: 15-21.

11. http://www.cenatra.salud.gob.mx/descargas/contenido/trasplante/reporte_anual_2011.pdf